Scopa James Paul

Scopa James Paul is listed in filings as Director at Aligos Therapeutics, Inc.. This profile follows SEC Form 4 activity through Dec 10, 2025, including 13 public disclosures. Recent filings connect the profile to Aligos Therapeutics, Inc. (ALGS) and Adverum Biotechnologies, Inc. (ADVM). The current snapshot covers public activity from Jun 20, 2024 to Dec 10, 2025. Reported amounts are shown as $22.8K to $77.0K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.